Weekly Report on the Greater Health Industry: Shanghai Ninth People's Hospital Tops Innovation Translation for Two Consecutive Years; Bogong Tech Launches Intelligent Stem Cell Robotics Solutions

Top Transformation for Two Consecutive Years: Insights from Shanghai Ninth People's Hospital on Innovation and Transformation

Shanghai Ninth People's Hospital Ranks First for Two Consecutive Years in Medical Innovation and Transformation. The hospital emphasizes the construction of scientific research platforms, possessing abundant clinical resources and multiple research platforms that provide excellent conditions for doctors to conduct scientific research. Additionally, the hospital focuses on the protection and exploration of patent technologies, promoting the transformation of multiple achievements. These advantages have enabled Shanghai Ninth People's Hospital to achieve remarkable success in the medical field. (Source: Vbdata.cn)

Guangdong Bogong Sanluwu Robot Technology Co., Ltd. Develops Stem Cell Robotics Intelligent Solution

Guangdong Bogong Sanluwu Robot Technology Co., Ltd. has started the Stem Cell Robotics Medtech Center project at the Songshan Lake Biomedical Industry Base. The project aims to develop new intelligent medical equipment such as life science robots, filling a gap in China. Founder Zhaoqiang Liu applies robotics technology to the life sciences field, creating an intelligent medical product line that achieves automated cell storage and preparation. The project is expected to complete clinical trials and be promoted within three years. (Source: Arterial Network)

Chinese Innovation Drug with Annual Sales of $1.3 Billion Receives Accelerated Approval for New Indication in the U.S.

BeOne Medicines' self-developed drug "Zanubrutinib" achieves annual sales of $1.3 billion, with a new indication for follicular lymphoma receiving accelerated approval in the U.S., providing a new treatment option for patients in 70 global markets. This marks the company's fifth approved B-cell malignancy indication in the U.S., with its clinical development program enrolling over 5,000 participants. (China Pharmaceutical Network)

WuXi AppTec Group Plummets, WuXi AppTec Responds Promptly

Wuxi AppTec Shares Plunge Amid U.S. Senate Passage of Biosecurity Bill, Listing Company as "Biotech of Concern"

Simnova Completes RMB 200 Million Series A+ Financing

On March 11, 2024, Simnova, a biotechnology company based in Shenzhen, completed a RMB 200 million Series A+ financing round led by You Mountain Capital, with participation from Oriza Ventures, Pudao Capital, and Guochuang Qinzhi. Harvest Capital served as the financial advisor for this round. The proceeds will be used to advance the development of CAR-NK cell therapy, expand solid tumor programs, promote clinical validation of in vivo cell treatment technologies, deepen collaborations, and accelerate product commercialization. Investors are optimistic about the future of immune cell therapy and Simnova's technical capabilities and commercial potential. (Source: Arterial Network)

Suzhou Yinghui Medical Technology Co., Ltd. Completes Tens of Millions of Yuan in Series A1 Financing

Recently, Suzhou Yinghui Medical Technology Co., Ltd. ("Yinghui Medicine") successfully completed its Series A1 round of financing worth tens of millions of RMB. This equity financing round was exclusively invested by Shengyuan Zhiben. The proceeds will be used for Phase I clinical research of Yinghui Medicine's oncolytic virus product YH01. Suzhou Yinghui is an innovative oncolytic virus company in China with full industrial chain capabilities, including the design, construction, validation, process development, and large-scale production of oncolytic viruses, and its key technology is at an internationally leading level. (Source: Arterial Network)

Dashing Bio Completes Tens of Millions of Yuan in Series A+ Financing

Shenzhen Dashicheng Optical Technology Co., Ltd. (hereinafter referred to as "Dashicheng"), a supply chain solutions provider for cosmetic contact lenses, has recently completed a multi-million yuan A+ round of financing led by Shenzhen Capital Group. The proceeds will be used to accelerate the expansion of production lines for cosmetic contact lenses, the research and development of new products and materials, and the layout of global compliant markets. Previously, the company received investments from Nut Capital and Jiupai Capital. (Source: Arterial Network)

MicroLight Medical Completes Over 100 Million Yuan in Strategic Financing

Shenzhen Zhongke Weiguang Medical Device Technology Co., Ltd. ("Weiguang Medical" for short) has secured a strategic investment of over 100 million yuan. This round of financing was jointly invested by Huarui Investment, Guangzhou Industrial Investment Capital, and ZhuiGuang Hard Tech. The funds will be used for the continuous development of new products in the laser medical field, clinical registration, and further expansion into overseas markets. (Source: Arterial Network)

Retail Terminal Market Breaks Through 900 Billion in 2023! Physical Pharmacy Sales Ratio Drops to 67%

Data from MiNe Network shows that the market sales scale of retail terminals (physical pharmacies + online pharmacies) exceeded 900 billion yuan in 2023, a year-on-year increase of 6.5%; among which, the retail scale of physical pharmacies was 622.9 billion yuan, with both Chinese herbal slices and medicines achieving positive growth. In December 2023, the TOP20 therapeutic categories of chemical medicines were released, showing significant declines in drugs for colds, coughs, pharyngitis, and fever, while medicines for tonifying qi and blood, antiviral, and anti-tumor treatments became "star" categories. (Source: MiNe Network)

Beijing Medical Insurance Bureau and Other Three Departments Jointly Issued the "Several Measures on Effectively Promoting the Implementation of Long-Term Prescription Policies for Outpatient Chronic Diseases"

On March 5, 2024, the Beijing Municipal Medical Security Bureau, the Beijing Municipal Health Commission, and the Beijing Municipal Drug Administration jointly formulated the "Several Measures on Effectively Promoting the Implementation of Long-Term Prescription Policies for Outpatient Chronic Diseases." The Several Measures clearly promote consistency in the types and specifications of chronic disease medications available at tertiary medical institutions and community health service centers. For insured individuals receiving treatment and obtaining medication at community health service centers, the 10% personal upfront payment requirement for Category B drugs under medical insurance will be eliminated. The Beijing Municipal Medical Security Bureau and other departments have adopted multiple measures to address practical difficulties in implementing the long-term prescription policy, better fulfilling the long-term medication needs of patients with chronic diseases. In terms of strengthening drug allocation management, a defined scope of chronic diseases suitable for long-term prescriptions will be established, and medical institutions will scientifically plan drug inventory for commonly used chronic disease medications. For drugs required by chronic disease patients but not yet available, community health service centers will maintain proper drug registration and ensure timely procurement and delivery. (Source: Arterial Network)